AvalehtNVON • BMV
add
Novo Nordisk A/S
Viimane sulgemishind
1287,50 $
Tänane vahemik
1235,88 $ - 1272,02 $
Aasta vahemik
1124,00 $ - 2764,09 $
Turuväärtus
214,65 mld USD
Keskmine maht
2,30 tuh
P/E suhe
-
Dividendimäär
-
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(DKK) | märts 2025info | Y/Y muutus |
---|---|---|
Käive | 78,09 mld | 19,49% |
Põhitegevusega seonduv kulu | 26,41 mld | 11,95% |
Puhastulu | 29,03 mld | 14,28% |
Puhaskasumimarginaal | 37,18 | −4,37% |
Puhaskasum aktsia kohta | 6,53 | 14,96% |
EBITDA | 42,62 mld | 25,34% |
Tõhus maksumäär | 21,60% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(DKK) | märts 2025info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 41,55 mld | 346,63% |
Kogu vara | 489,16 mld | 63,64% |
Kõik kohustused | 350,62 mld | 75,30% |
Kogu omakapital | 138,54 mld | — |
Emiteeritud aktsiate arv | 4,44 mld | — |
Hinna ja väärtuse suhe P/B | 41,25 | — |
Varade tasuvus | 20,31% | — |
Kapitali tasuvus | 38,52% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(DKK) | märts 2025info | Y/Y muutus |
---|---|---|
Puhastulu | 29,03 mld | 14,28% |
Põhitegevuse rahakäive | 24,59 mld | 71,80% |
Investeeringute raha | −6,67 mld | −268,68% |
Finantseerimise raha | 5,45 mld | 120,66% |
Raha ja raha ekvivalentide muutus | 23,28 mld | 388,58% |
Tasuta rahavoog | 22,11 mld | 247,28% |
Teave
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph 𓃒. Wikipedia
Tegevjuht
Asutatud
21. dets 1923
Peakontor
Veebisait
Töötajate arv
77 406